CV Sciences earnings release, May 14, 2026

CV Sciences, Inc. (CVSI) · Form 8-K, Item 2.02 · Filed · SEC filing

CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

San Diego, CA - May 14, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2026.

First Quarter 2026 and Recent Financial and Operating Highlights

• Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025 and compared to $3.3 million for the fourth quarter 2025;

• Recognized gross margin of 48.9% for the first quarter 2026 compared to 46.0% for the first quarter 2025 and compared to 50.5% for the fourth quarter 2025;

• Cash balance of $0.3 million at quarter and year end;

• Reduced operating expenses by 13.3% to $1.9 million for the first quarter 2026 compared to $2.2 million for the first quarter 2025, excluding benefit from reversal of accrued payroll taxes;

• Recognized an adjusted EBITDA loss of $0.1 million for the first quarter 2026 compared to $0.3 million for first quarter 2025 and compared to positive adjusted EBITDA of $0.1 million for the fourth quarter 2025;

• Launched EMPOWR, a plant-based protein and creatine formula designed for total wellness, and

• Completed successful debt restructuring designed to strengthen financial position and fuel future growth.

“We are pleased with our first quarter 2026 results, which reflects continued progress in strengthening our operational and financial foundation,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “Our gross margins remained strong during the quarter, and we expect additional improvement in the second half of 2026 as we continue optimizing our product mix and operating structure. We remain focused on disciplined expense management, operational efficiency, and driving the business toward sustainable profitability and positive cash flow.”

“During the quarter, we also completed a successful debt restructuring that improved our financial flexibility and positions us to pursue strategic growth initiatives more effectively. At the same time, we believe the current market environment presents attractive opportunities to accelerate growth through strategic acquisitions that complement our existing brands and leverage our operational platform. We are committed to pursuing opportunities selectively and with financial discipline, while continuing to focus on long-term value creation for our shareholders.”

Operating Results - First Quarter 2026 Compared to First Quarter 2025

Sales for the first quarter 2026 were $3.2 million, a decrease of 11.4% from $3.6 million in the first quarter 2025. The decline is driven by lower sales volume due to restrictive regulations at the federal level and in certain states. The total number of units sold during the first quarter 2026 decreased by 12.2%, partially offset by minor increases in average sales prices. In addition, 43% of our net revenue for the first quarter 2026 was from new products launched since January 1, 2023. During this time period, we launched 45 new products.

We generated an operating loss of $0.3 million in the first quarter 2026, compared to operating income of $11,000 in the first quarter 2025. The change is mostly due to the reversal of accrued payroll taxes of $0.5 million in the first quarter 2025, offset by reduced operating expenses. We had negative adjusted EBITDA of $0.1 million for the first quarter 2026 compared to $0.3 million in the first quarter 2025. The improvement is mostly due to lower operating expenses.

Conference Call and Webcast

The Company will host a conference call and webcast to discuss these results today at 4:30 pm EDT/1:30 pm PDT. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1760203&tp_key=9a8cb9d283. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. A telephone replay will be available approximately three hours after the call concludes, and will be available through Thursday, May 21, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13760149.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Forward Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (in thousands, except per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Product sales, net3,1953,606
Cost of goods sold1,6331,948
Gross profit1,5621,658
Operating expenses:Research and development1830
Operating expenses:Selling, general and administrative1,8622,139
Operating expenses:Benefit from reversal of accrued payroll taxes-522
Operating expenses:Total operating expenses1,8801,647
Operating expenses:Operating income (loss)-31811
Operating expenses:Gain on extinguishment of debt-20-38
Operating expenses:Change in fair value of convertible notes252
Operating expenses:Interest expense, net93151
Operating expenses:Loss before income taxes-643-102
Operating expenses:Income tax expense7
Operating expenses:Net loss-643-109
Operating expenses:Weighted average common shares outstanding, basic and diluted186,920184,264
Operating expenses:Net loss per common share, basic and diluted00

Income Statement

Three Months Ended March 31, (in thousands, except per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net loss - GAAP-643-109
Stock-based compensation (1)148118
Change in fair value of convertible notes (2)252
Benefit from reversal of accrued payroll tax (3)-522
Gain on debt extinguishment (4)-20-38
Note discount (5)91149
Net loss - non-GAAP-172-402
Diluted EPS - GAAP00
Diluted EPS - non-GAAP00
Shares used to calculate diluted EPS - GAAP and non-GAAP186,920184,264

Income Statement

Three Months Ended March 31, — A reconciliation from our net loss to Adjusted EBITDA, a non-GAAP measure, for the three months ended March 31, 2026 and 2025 is detailed below (in thousands):

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net loss-643-109
Depreciation expense1676
Amortization expense76
Interest expense, net93151
Income tax expense7
EBITDA-527131
Stock-based compensation (1)148118
Change in fair value of convertible notes (2)252
Benefit from reversal of accrued payroll tax (3)-522
Gain on debt extinguishment (4)-20-38
Adjusted EBITDA-147-311

Balance Sheet

March 31, 2026 — (in thousands, except per share data)

March 31, 2026December 31, 2025
Current assets:Cash309278
Current assets:Accounts receivable, net391402
Current assets:Inventory3,9024,087
Current assets:Prepaid expenses and other393366
Current assets:Total current assets4,9955,133
Current assets:Property and equipment, net329344
Current assets:Right of use assets282347
Current assets:Intangibles, net6876
Current assets:Goodwill1,0011,015
Current assets:Other assets4747
Current assets:Total assets6,7226,962
Current liabilities:Accounts payable1,0801,044
Current liabilities:Accrued expenses2,6472,447
Current liabilities:Current portion of operating lease liabilities246247
Current liabilities:Convertible notes, at fair value1,135
Current liabilities:Current portion of long-term debt, net721,262
Current liabilities:Total current liabilities5,1805,000
Current liabilities:Operating lease liabilities37100
Current liabilities:Debt, net of debt issuance costs387
Current liabilities:Deferred tax liability77
Current liabilities:Total liabilities5,2245,494
Stockholders' equityCommon stock, par value $0.0001; 790,000 shares authorized as of March 31, 2026 and December 31, 2025; 193,458 and 184,264 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1918
Stockholders' equityAdditional paid-in capital90,02989,330
Stockholders' equityAccumulated deficit-88,582-87,939
Stockholders' equityAccumulated other comprehensive income3259
Stockholders' equityTotal stockholders' equity1,4981,468
Stockholders' equityTotal liabilities and stockholders' equity6,7226,962

Cash Flow

Three Months Ended March 31, — (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
OPERATING ACTIVITIESNet loss-643-109
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Depreciation and amortization2382
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Stock-based compensation148118
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Amortization of debt discount91149
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Amortization of right of use assets6552
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Fair value adjustment for convertible notes252
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Gain on debt extinguishment-20-38
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Benefit from reversal of accrued payroll taxes-522
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities:Other-1280
Change in operating assets and liabilities:Accounts receivable, net22100
Change in operating assets and liabilities:Inventory174536
Change in operating assets and liabilities:Prepaid expenses and other-2818
Change in operating assets and liabilities:Accounts payable and accrued expenses92-486
Full release

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.

Contact Information ir@cvsciences.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · CV Sciences earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.